Our friends at Statista yesterday published this chart showing Google/Alphabet’s largest acquisitions over the years. . . . → Read More: Infographic – Google’s Largest Acquisitions
|
|||||
|
|
A company developing personal cancer therapies that genetically engineer a patient’s immune system cells is being acquired in a deal valued at $11.9 billion. . . . → Read More: Engineered T-Cell Company Acquired for $11.9 Billion  One comment - (Comments are closed)  Finance  biomedical, biotechnology, cancer, clinical trials, entrepreneurs, equity, investment, licensing, life sciences, merger, NIH, pharmaceuticals A company providing whole genome analysis is acquiring an enterprise developing open-source computational software for biomedical uses, such as precision medicine. . . . → Read More: Genomics Company Acquires Open-Source Biomedical Platform Comments are closed Finance biomedical, computer science, engineering, entrepreneurs, genomics, life sciences, mathematics, medical device, merger, physical sciences, software, university Drug maker Eli Lilly and Company is acquiring CoLucid Pharmaceuticals, a developer of treatments for migraine pain and associated symptoms. . . . → Read More: Lilly Acquires Migraine Therapy Company in $960M Deal Comments are closed Finance biomedical, clinical trials, equity, heart disease, investment, licensing, life sciences, merger, pharmaceuticals A clinical trial testing a treatment for heart failure using a patient’s own bone marrow stem cells is recruiting participants at the first two study sites. . . . → Read More: Trial to Test Stem Cells for Treating Heart Failure One comment - (Comments are closed) Regulations biomedical, biotechnology, clinical trials, heart disease, life sciences, medical device, merger, pharmaceuticals, stem cells, university Drug maker Novartis is acquiring Selexys Pharmaceuticals Corp., a developer of treatments for pain episodes associated with sickle cell disease, for $665 million. . . . → Read More: Novartis Acquires Sickle-Cell Drug Developer Comments are closed Finance biomedical, biotechnology, clinical trials, equity, genomics, investment, life sciences, merger, pharmaceuticals A company with a technology for converting drugs given by intravenous infusion into pills and capsules was acquired Grünenthal Group, a provider of pain medications. . . . → Read More: Infusion-to-Oral Drug Delivery Company Acquired One comment - (Comments are closed) Finance biomedical, cancer, clinical trials, equity, Europe, life sciences, merger, pharmaceuticals Google is acquiring Eyefluence Inc., developer of a technology that allows individuals to interact with computers, phones, and other devices using only their eyes. . . . → Read More: Google Acquires Visual Interaction Tech Company One comment - (Comments are closed) Finance computer science, engineering, entrepreneurs, life sciences, mathematics, merger, physical sciences, software, venture capital Scanning electron micrograph of a human T-cell lymphocyte (National Institute of Allergy and Infectious Diseases, NIH) 11 January 2016. Juno Therapeutics is gaining single-cell sequencing technology for cancer immunotherapies through the buy-out of biotechnology company AbVitro Inc., and licensing part of that technology to pharmaceutical company Celgene Corp. The AbVitro acquisition is valued at . . . → Read More: Juno Acquires Biotech, Licenses Cell Sequencing Tech Comments are closed Finance, Intellectual property biomedical, biotechnology, cancer, entrepreneurs, equity, genomics, investment, licensing, life sciences, merger, pharmaceuticals, university Downtown Vancouver (Magnus Larsson, Flickr) 8 January 2016. Two biotechnology companies in Vancouver agreed to collaborate on developing antibody treatments for cancer, with an option to merge their enterprises later on. The deal calls for Zymeworks Inc. to make an undisclosed equity investment in Kairos Therapeutics Inc. Zymeworks is also receiving $US 61.5 million . . . → Read More: Biotechs to Develop Antibody Therapies, Explore Merger One comment - (Comments are closed) Finance, Joint ventures/collaborations biomedical, biotechnology, Canada, cancer, debt, equity, investment, life sciences, merger, pharmaceuticals, venture capital |
A Thinking Person’s Artificial Intelligence Do You Want Your Bacon CRISPR? Health Care, Precisely One Person at a Time Let Guinea Pigs be Guinea Pigs Look Out Pharma. The Tech Industry is After You |
|||
|
Copyright © 2017 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
